OncoSec Medical (OncoSec Medical) Operating Income : $-32.65 Mil (TTM As of Jan. 2023)

View and export this data going back to 1986. Start your Free Trial

What is OncoSec Medical Operating Income?

OncoSec Medical's Operating Income for the three months ended in Jan. 2023 was $-7.66 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jan. 2023 was $-32.65 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. OncoSec Medical's Operating Income for the three months ended in Jan. 2023 was $-7.66 Mil. OncoSec Medical's Revenue for the three months ended in Jan. 2023 was $0.00 Mil. Therefore, OncoSec Medical's Operating Margin % for the quarter that ended in Jan. 2023 was %.

OncoSec Medical's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. OncoSec Medical's annualized ROC % for the quarter that ended in Jan. 2023 was -530.09%. OncoSec Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2023 was -854.47%.

OncoSec Medical Operating Income Historical Data

The historical data trend for OncoSec Medical's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical Operating Income Chart

OncoSec Medical Annual Data

Trend

Jul13

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Operating Income

Get a 7-Day Free Trial

-36.11

-30.42

-43.41

-48.38

-37.01

OncoSec Medical Quarterly Data
	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23
Operating Income	Get a 7-Day Free Trial															-9.42	-9.55	-8.13	-7.31	-7.66

OncoSec Medical Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jan. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-32.65 Mil.

OncoSec Medical (OTCPK:ONCSQ) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

OncoSec Medical's annualized ROC % for the quarter that ended in Jan. 2023 is calculated as:

	ROC % (Q: Jan. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Oct. 2022 )	+	Invested Capital (Q: Jan. 2023 ))	/ count )
=	-30.656 * ( 1 - -0.04% )	/	( (7.689	+	3.882)	/ 2 )
=	-30.6682624	/	5.7855
=	-530.09 %

where

	Invested Capital		(Q: Oct. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	14.439	-	5.027	-	( 5.73	-	max(0, 6.91	-	8.633	+	5.73	))
=	7.689

	Invested Capital		(Q: Jan. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	8.871	-	5.778	-	( 3.683	-	max(0, 7.231	-	6.442	+	3.683	))
=	3.882

Note: The Operating Income data used here is four times the quarterly (Jan. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

OncoSec Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jan. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Oct. 2022		Q: Jan. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-27.296	/	( ( (4.865 + max(-2.369, 0))	+	(1.524 + max(-3.134, 0)) )	/	2 )
=	-27.296	/	( ( 4.865	+	1.524 )	/	2 )
=	-27.296	/	3.1945
=	-854.47 %

where Working Capital is:

	Working Capital		(Q: Oct. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.903)	-	(5.027	+	0	+	0.245)
=	-2.369

	Working Capital		(Q: Jan. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.759)	-	(5.778	+	0	+	0.115)
=	-3.134

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jan. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

OncoSec Medical's Operating Margin % for the quarter that ended in Jan. 2023 is calculated as:

Operating Margin %	=	Operating Income (Q: Jan. 2023 )	/	Revenue (Q: Jan. 2023 )
	=	-7.664	/	0
	=	%

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

OncoSec Medical Operating Income Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoSec Medical (OncoSec Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (OTCPK:ONCSQ) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

24 North Main Street, Pennington, NJ, USA, 08534

Website

https://www.oncosec.com

OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

Executives

Robert J Delaversano	officer: Principal Accounting Officer	217 W. MAIN STREET, SOMERVILLE NJ 08876
Spahr Stephany Foster	director	C/O ONCOSEC MEDICAL, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Robert H. Arch	officer: President and CEO	C/O ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
George Chi	officer: Chief Financial Officer	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Lin Shi	director	24 NORTH MAIN STREET, PENNINGTON NJ 08534-2218
Margaret Dalesandro	director	ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Yuhang Zhao	director	6 HORTON DR., CHESTER NJ 07930
Brian A Leuthner	officer: Chief Operating Officer	200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Daniel J. O'connor	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
China Grand Pharmaceutical & Healthcare Holdings Ltd	10 percent owner, other: See Remarks	UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000
Alpha Holdings, Inc.	director, 10 percent owner	GANGNAM-GU APGUJEONG-RO 62-GIL 17-10, SEOUL M5 06016
Kellie Malloy Foerter	officer: Chief Operating Officer	C/O ONCOSEC MEDICAL INCORPORATED, 24 N. MAIN STREET, PENNINGTON NJ 08534-2218
Herbert Kim Lyerly	director	C/O ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534-2218
Chao Zhou	director	UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000
Grand Decade Developments Ltd	10 percent owner, other: See Remarks	UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000